Impact of Peptide Receptor Radionuclide Therapy using Y-90 DOTA-TATE/Lu-177 DOTA-TATE on renal tubular function: Long term follow-up

被引：0
|
作者：
Prasad, V.
Baum, R. P.
机构：
[1] Zent Klin Bad Berka GmbH, Dept Nucl Med, Bad Berka, Germany
[2] Zent Klin Bad Berka GmbH, Ctr PET CT, Bad Berka, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2008年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S351 / S351
页数：1
相关论文
共 50 条
  • [11] Dosimetry in peptide receptor radionuclide therapy (PRRNT): comparative results using Lu-177 DOTA-TATE, DOTA-NOC und DOTA-TOC
    Schuchardt, C.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S244 - S244
  • [12] Individual effective half-life in Lu-177 Dota-Tate therapy
    Fitschen, J.
    Knoop, B. O.
    Knapp, W. H.
    Geworski, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S339 - S339
  • [13] Lu-177 DOTA-TATE for peptide receptor radionuclide therapy (PRRT): organ-, tumor- and blood kinetics
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S338 - S339
  • [14] Treatment with tandem [90Y]DOTA-TATE an [177Lu]DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results
    Seregni, E.
    Maccauro, M.
    Coliva, A.
    Castellani, M. R.
    Bajetta, E.
    Aliberti, G.
    Vellani, C.
    Chiesa, C.
    Martinetti, A.
    Bogni, A.
    Bombardieri, E.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 54 (01): : 84 - 91
  • [15] Preliminary Results of Lu-177 DOTA-TATE Therapy in Patients with Neuroendocrine Tumor
    Hekimsoy, T.
    Isgoren, S.
    Gorur, G. Daglioz
    Demir, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S596 - S596
  • [16] Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC
    Wehrmann, Christiane
    Senftleben, Stefan
    Zachert, Carolin
    Mueller, Dirk
    Baum, Richard P.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (03) : 406 - 416
  • [17] Repeated cycles of peptide receptor radionuclide therapy (PRRT) - Side-effects and response to the radioisotope 90Y-DOTA-TATE or 90Y/177Lu DOTA-TATE therapy in patients with disseminated NET
    Sowa-Staszczak, Anna
    Kunikowska, Jolanta
    Krolicki, Leszek
    Mikolajczak, Renata
    Pawlak, Dariusz
    Stefanska, Agnieszka
    Tomaszuk, Monika
    Trofimiuk, Malgorzata
    Pach, Dorota
    Hubalewska-Dydejczyk, Alicja
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [18] Investigation of the influence of metallic impurities on the 90Y and 177Lu labelling yield of DOTA and DOTA-TATE
    Pawlak, D
    Korsak, A
    Mikolajczak, R
    Sasinowska, I
    Parus, JL
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S388 - S388
  • [19] Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-Tyr3-OCTREOTATE (Y-90 DOTA-TATE) in patients with metastatic neuroendocrine tumors
    Baum, RP
    Söldner, J
    Schmücking, M
    Niesen, A
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S238 - S238
  • [20] Peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE
    Prado-Wohlwend, S.
    Bernal-Vergara, J. C.
    Utrera-Costero, A.
    Canon-Sanchez, J. R.
    Agudelo-Cifuentes, M.
    Bello-Arques, P.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2022, 41 (01): : 55 - 65
12345